Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

MDNA

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corp
から:
次の項目別のソート:
 Showing the most relevant articles for your search:TSX:MDNA
日付受信時刻ニュースソース見出しコード企業名
2024/04/2621 : 16PR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - MDNATSX:MDNAMedicenna Therapeutics Corp
2024/04/2621 : 14PR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - MDNATSX:MDNAMedicenna Therapeutics Corp
2024/04/2621 : 09PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - MDNATSX:MDNAMedicenna Therapeutics Corp
2024/04/2621 : 07PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - MDNATSX:MDNAMedicenna Therapeutics Corp
2020/06/1120 : 00PR Newswire (Canada)Medicenna to Present at Raymond James Human Healthcare Innovation ConferenceTSX:MDNAMedicenna Therapeutics Corp
2020/06/1120 : 00PR Newswire (US)Medicenna to Present at Raymond James Human Healthcare Innovation ConferenceTSX:MDNAMedicenna Therapeutics Corp
2020/05/2921 : 15PR Newswire (US)Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
2020/05/2921 : 15PR Newswire (Canada)Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
2020/05/2921 : 05PR Newswire (US)Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
2020/05/2921 : 05PR Newswire (Canada)Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
2020/05/1520 : 30PR Newswire (US)Medicenna Announces March 31, 2020 Year-End ResultsTSX:MDNAMedicenna Therapeutics Corp
2020/05/1520 : 30PR Newswire (Canada)Medicenna Announces March 31, 2020 Year-End ResultsTSX:MDNAMedicenna Therapeutics Corp
2020/05/0420 : 00PR Newswire (Canada)Medicenna Announces Upcoming Presentations at the ASCO Annual MeetingTSX:MDNAMedicenna Therapeutics Corp
2020/05/0420 : 00PR Newswire (US)Medicenna Announces Upcoming Presentations at the ASCO Annual MeetingTSX:MDNAMedicenna Therapeutics Corp
2020/04/1522 : 23PR Newswire (Canada)Medicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public OfferingTSX:MDNAMedicenna Therapeutics Corp
2020/03/2520 : 00PR Newswire (US)Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate StudyTSX:MDNAMedicenna Therapeutics Corp
2020/03/2520 : 00PR Newswire (Canada)Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate StudyTSX:MDNAMedicenna Therapeutics Corp
2020/03/1722 : 14PR Newswire (Canada)Medicenna Announces Closing of Public Offering of $35 MillionTSX:MDNAMedicenna Therapeutics Corp
2020/03/1222 : 00PR Newswire (Canada)Medicenna Announces Intention to File Final Short Form ProspectusTSX:MDNAMedicenna Therapeutics Corp
2020/03/0423 : 37PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - MDNATSX:MDNAMedicenna Therapeutics Corp
2020/03/0423 : 36PR Newswire (Canada)IIROC Trade Resumption - MDNATSX:MDNAMedicenna Therapeutics Corp
2020/03/0423 : 25PR Newswire (Canada)Medicenna Announces Pricing of $35 Million Overnight Marketed Offering of Common SharesTSX:MDNAMedicenna Therapeutics Corp
2020/03/0407 : 14PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - MDNATSX:MDNAMedicenna Therapeutics Corp
2020/03/0407 : 11PR Newswire (Canada)IIROC Trading Halt - MDNATSX:MDNAMedicenna Therapeutics Corp
2020/03/0406 : 35PR Newswire (Canada)Medicenna Announces Overnight Marketed Offering of Common SharesTSX:MDNAMedicenna Therapeutics Corp
2020/02/1321 : 30PR Newswire (US)Medicenna Reports Third Quarter Fiscal 2020 Financial ResultsTSX:MDNAMedicenna Therapeutics Corp
2020/02/1321 : 30PR Newswire (Canada)Medicenna Reports Third Quarter Fiscal 2020 Financial ResultsTSX:MDNAMedicenna Therapeutics Corp
2020/01/1321 : 00PR Newswire (US)Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control ArmTSX:MDNAMedicenna Therapeutics Corp
2020/01/1321 : 00PR Newswire (Canada)Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control ArmTSX:MDNAMedicenna Therapeutics Corp
2020/01/0823 : 13PR Newswire (US)Medicenna Receives $1.3 Million Through Early Warrant ExercisesTSX:MDNAMedicenna Therapeutics Corp
 Showing the most relevant articles for your search:TSX:MDNA

最近閲覧した銘柄

Delayed Upgrade Clock